We’re expanding our US manufacturing capacity. This year, we plan to invest 4.1 billion US dollars (approx 27 billion Danish kroner) to build a second fill and finishing manufacturing facility in Clayton, North Carolina. With this investment, we will create 1000 new jobs and grow our ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases. Learn more about the news here 👉 https://lnkd.in/gu4MH2U #NovoNordisk #DrivingChange #Manufacturing #Production
Novo Nordisk
Produktion af lægemidler
Driving change to defeat serious chronic diseases, built upon our heritage in diabetes.
Om os
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
- Websted
-
https://www.novonordisk.com
Eksternt link til Novo Nordisk
- Branche
- Produktion af lægemidler
- Virksomhedsstørrelse
- Over 10.001 medarbejdere
- Hovedkvarter
- Bagsværd
- Type
- Aktieselskab
- Grundlagt
- 1923
- Specialer
- Pharmaceuticals, Insulin, obesity, Rare Diseases og Diabetes
Beliggenheder
Medarbejdere hos Novo Nordisk
-
Thomas Røygaard
PMO | Digital Transformation | Leading Program, Project and Portfolio Management | Governance | Change Management
-
Naras Eechambadi
Global Leader in Data & AI | C-Suite Executive | Board Director | DataIQ Top10 | Executive Coach
-
Sören Meelby
Strategic Alliance Evangelist | Cultivating Partnerships for Collective Impact & Social Good
-
Henrik Vestergaard
Opdateringer
-
Genetics is one of many factors that play a role in a person’s likelihood of developing obesity. Did you know that the heritability of obesity is as high as 40-70%? Learn more about the multiple factors impacting people living with obesity: https://lnkd.in/eCyWpsQ #NovoNordisk #DrivingChange #Obesity
-
We’re on a mission to drive change for millions of people living with chronic diseases and we need talents to help shape the future. Did you know that we currently have around 1,000 open positions across the world? Check out our career site to see if there is a match for you: https://lnkd.in/dfHdaYP #NovoNordisk #DrivingChange #Career
-
It takes more than medicine to defeat chronic diseases. It takes sport, song, culture, collaboration, listening and partnership. Just ask these inspiring people who are making big changes to the health of their communities - each in their own unique way. #NovoNordisk #DrivingChange #Health
-
Missed anything from #ISTH2024? Catch up on the exciting updates from the International Society on #Thrombosis and #Haemostatis at Novo Nordisk CongressHub 👉 https://bit.ly/45rxuxI
-
28 June marks the anniversary of the pivotal Stonewall uprising in 1969, which ignited the modern LGBTQ+ rights movement. We have partnered with Stonewall to focus on everyday inclusion for our LGBTQ+ colleagues, fostering an environment where everyone can thrive. To kick off the partnership, we are joining their Rainbow Laces campaign, which aims to spark dialogue around how we can all become active allies for LGBTQ+ inclusion, both in the workplace and in making sport everyone's game. The ask is simple – lace up to speak up! Learn more abut our partnership here: https://lnkd.in/dfT5m4AS
-
The only way we can overcome low awareness of #sicklecelldisease and the stigmas faced by people living with it is by starting more conversations. This #WorldSickleCellDay we’re asking you to join us in raising awareness. Have one conversation with one other person about Sickle Cell Disease today. You can learn more about it here: https://lnkd.in/dM-YdTN We are committed to a future where it is possible to #liveunlimited with sickle cell disease, are you? #WorldSickleCellDay #WSCD2024
-
Exciting developments are underway at our production site in Chartres, France! This week, members of our leadership team and board visited the site to see how we’re investing in and significantly expanding our facilities to meet the needs of millions of people living with diabetes, obesity, and other serious chronic diseases. By 2028, we aim to welcome 500 new colleagues, and increase our capacity to serve many more patients. A special thanks to our 1700 dedicated colleagues at Chartres, who produce life-saving treatments.
-
Did you know? MASH, or metabolic dysfunction-associated steatohepatitis, is a serious, progressive, metabolic disease affecting the liver, which can be fatal if not managed properly. It is often described as a ‘silent disease’ due to the lack of specific symptoms in the early stages of the disease, which often contributes to a delay in diagnosis. 13 June is Global #FattyLiverDay 🌎 Learn more about living with the condition and the impact of a late diagnosis from Tania. Watch Tania’s story here: https://lnkd.in/dAw55qZV At Novo Nordisk, we are committed to continuing our research with the ambition of developing innovations that can help address the underlying cause of this disease. We hope to double diagnostic rates for people living with moderate to advanced MASH by 2027 💙
-
The count down is on and we're looking forward to #ISTH2024 in Bangkok! Follow along online between 22 - 26 June as we address the unmet needs in haemophilia, and raise awareness of rare diseases 👇 https://bit.ly/4bYBdoI #ChangingHaemophilia
Discover more at Novo Nordisk CongressHub
Tilsvarende sider
Aktie
NVO
NYSE
20 minutters forsinkelse
129,99 US$
-5,43 (-4,01 %)
- Åbningspris
- 134,94
- Lavpunkt
- 126,83
- Højdepunkt
- 134,97
Data fra Refinitiv
Få flere oplysninger påFinansiering
Seneste runde
Post IPO-egenkapital22.000.000,00 US$